News
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) on March 25 and set a price target of $20.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback